NCT02735629View on ClinicalTrials.gov

Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

PHASE2UnknownINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

September 30, 2016

Conditions

Opiate Induced Respiratory Depression

Interventions

DRUG

CX1739 - 300 mg

Ampakine CX1739 - 300 mg

DRUG

CX1739 - 600 mg

CX1739 - 600 mg

DRUG

CX1739 - 900 mg

CX1739 - 900 mg

DRUG

Placebo

Placebo to 300 mg CX1739

Trial Locations (1)

27710

Duke Clinical Research Unit, Durham

Sponsors

Collaborators (1)

Duke University

All Listed Sponsors

collaborator

Duke University

OTHER

lead

RespireRx

INDUSTRY

NCT02735629 - Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia | Biotech Hunter | Biotech Hunter